meplazumab   Click here for help

GtoPdb Ligand ID: 11026

Synonyms: HP6H8 | Ketantin®
Antimalarial Ligand
Compound class: Antibody
Comment: Meplazumab is a humanized IgG2 monoclonal antibody that targets CD147 (basigin). It is being developed by Jiangsu Pacific Meinuoke Bio Pharmaceutical.

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.

SARS-CoV-2 and COVID-19: SARS-CoV-2 may utilise CD147 as an additional entry receptor to infect host cells [2]. Meplazumab can block this interaction between CD147 and SARS-CoV-2 spike protein.
No information available.
Summary of Clinical Use Click here for help
Meplazumab has been advanced to early stage clinical trial as a novel therapy for malaria. In response to the SARS-CoV-2 pandemic its developers have initiated studies to evaluate if CD147 blockade can provide clinical benefit in patients with COVID-19. Preliminary results are reported in an article that has been posted on the medRxiv preprint server [1]. In this paper the authors report that meplazumab (three 10mg i.v. doses on days 1, 2, and 5) improved recovery of patients with SARS-CoV-2 pneumonia, and that it had a favourable safety profile.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
In P. falciparum, meplazumab disrupts the interaction between CD147 (expressed on the surface of the host erythrocyte) and rhoptry-associated protein 2 (RAP2, a parasite-secreted rhoptry protein). The interaction between CD147 and RAP2 is essential for erythrocyte invasion by P. falciparum [4].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04275245 Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia Phase 1/Phase 2 Interventional Tang-Du Hospital
NCT04327310 Clinical Study of Meplazumab to Treat With Malaria Phase 1 Interventional Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd